Score Overview
Explore the 2021 public Archive ranking →
Where AstraZeneca PLC has ranked, year by year
Showing 20 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- AZN
2014: 29.9% · 2021: 64.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-14 | $ 163.78 | — |
1 Year2025-09-12 | $ 156.43 | 4.70% |
5 Years2021-09-14 | $ 100.87 | 62.37% |
10 Years2016-09-14 | $ 50.06 | 227.20% |
20 Years2006-09-14 | $ 27.16 | 6x |
30 Years1996-09-13 | $ 8.22 | 19x |
All Time1993-05-17 | $ 2.98 | 55x |
| Period | Last Price2026-09-14 | 1 Year2025-09-12 | 5 Years2021-09-14 | 10 Years2016-09-14 | 20 Years2006-09-14 | 30 Years1996-09-13 | All Time1993-05-17 |
|---|---|---|---|---|---|---|---|
| Price | $ 163.78 | $ 156.43 | $ 100.87 | $ 50.06 | $ 27.16 | $ 8.22 | $ 2.98 |
| Return | — | 4.70% | 62.37% | 227.20% | 6x | 19x | 55x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 61.17B | $ 10.41B | $ 4.96B |
| 2025 | $ 58.73B | $ 10.25B | $ 5.74B |
| 2024 | $ 54.07B | $ 7.03B | $ 5.52B |
| 2023 | $ 45.81B | $ 5.95B | $ 5.86B |
| 2022 | $ 44.35B | $ 3.28B | $ 6.24B |
| 2021 | $ 37.41B | $ 112M | $ 6.39B |
| 2020 | $ 26.61B | $ 3.19B | $ 7.99B |
| 2019 | $ 24.38B | $ 1.33B | $ 6.21B |
| 2018 | $ 22.09B | $ 2.15B | $ 5.68B |
| 2017 | $ 22.46B | $ 3.00B | $ 4.55B |
| 2016 | $ 23.00B | $ 3.49B | $ 5.90B |
| 2015 | $ 24.70B | $ 2.82B | $ 6.85B |
| 2014 | $ 26.54B | $ 1.23B | $ 7.15B |
| 2013 | $ 25.80B | $ 2.55B | $ 10.01B |
| 2012 | $ 27.97B | $ 6.24B | $ 8.52B |
| 2011 | $ 33.59B | $ 9.91B | $ 11.81B |
| 2010 | $ 33.26B | $ 8.05B | $ 12.55B |
| 2009 | $ 32.80B | $ 7.52B | $ 11.42B |
| 2008 | $ 31.60B | $ 6.10B | $ 4.39B |
| 2007 | $ 29.55B | $ 5.59B | $ 6.04B |
| 2006 | $ 26.47B | $ 6.04B | $ 7.76B |
| 2005 | $ 23.95B | $ 4.70B | $ 6.60B |
| 2004 | $ 21.42B | $ 3.66B | $ 5.26B |
| 2003 | $ 18.84B | $ 3.03B | $ 3.95B |
| 2002 | $ 17.84B | $ 2.83B | $ 4.68B |
| 2001 | $ 16.48B | $ 4.15B | $ 5.46B |
| 2000 | $ 18.11B | $ 2.54B | $ 4.45B |
| 1999 | $ 15.13B | $ 1.14B | $ 3.28B |
| 1998 | $ 11.31B | $ 1.18B | $ 615M |
| 1997 | $ 8.58B | $ 1.20B | $ 1.20B |
| 1996 | $ 9.18B | $ 1.10B | $ 1.66B |
| 1995 | $ 7.56B | $ 519M | $ 1.22B |
| 1994 | $ 7.00B | $ 692M | $ 1.14B |
| IPO1993 | $ 6.56B | $ 637M | $ 1.55B |
AstraZeneca PLC fundamental performance
Between 2020 and 2025, revenue grew from $ 26.61B to $ 58.73B and net income grew from $ 3.19B to $ 10.25B. Revenue increased in every one of those 5 years; net income in every one.
Between 2015 and 2025, revenue grew from $ 24.70B to $ 58.73B and net income grew from $ 2.82B to $ 10.25B. Revenue increased in 8 of those 10 years; net income in 6.
AstraZeneca PLC currently holds a 20-year HDB Score of 4.5 out of 10. How the HDB Score is calculated.
Membership
Continue AZN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,827 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
